New York, USA, April 03, 2023 (GLOBE NEWSWIRE) -- Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte, Eli Lilly, Gilead, Genentech Expected to Boost Endometrial Cancer Market
The endometrial cancer market to propel in the coming years owing to the factors such as the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate.
DelveInsight’s Endometrial Cancer Market Insights report includes a comprehensive understanding of current treatment practices, endometrial cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Endometrial Cancer Market Report
- As per DelveInsight analysis, the endometrial cancer market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives. More than 80% of people with uterine cancer survive for five years or longer after receiving the diagnosis. Endometrial cancer comprises about 4% of all cancers in women globally.
- Leading endometrial cancer companies such as AstraZeneca, Karyopharm therapeutics, Evergreen therapeutics, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte Corporation, Eli Lilly and Company, Gilead Sciences, Genentech, and others are developing novel endometrial cancer drugs that can be available in the endometrial cancer market in the coming years.
- Some of the key therapies for endometrial cancer treatment include Lynparza + Imfinzi, Selinexor, EG-007, IMGN853, Pembrolizumab, TSR-042, Everolimus, Giredestrant, ONC201, Abemaciclib + Letrozole +/- Metformin, Sacituzumab Govitecan, Atezolizumab + Bevacizumab, Copanlisib + fulvestrant, IMGN151, Retifanlimab, and others.
- Several endometrial cancer therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major endometrial cancer market share @ Endometrial Cancer Market Report
Endometrial Cancer Overview
Endometrial cancer occurs when cells in the endometrium (the inner lining of the uterus) grow uncontrollably. Cancerous cells can arise in almost any body portion and spread to other parts. Endometrial cancer is also known as uterine cancer. Other types of cancer, such as uterine sarcoma, can develop in the uterus, but they are far less common than endometrial cancer. Endometrial cancer is often detected early because it frequently produces abnormal vaginal bleeding. When endometrial cancer is discovered early, surgically removing the uterus often cures it. The most common type of endometrial cancer (type 1) grows slowly.
The most common symptom of endometrial cancer is abnormal vaginal bleeding. This includes changes in the length or heaviness of menstrual periods, vaginal bleeding or spotting between menstrual periods, and vaginal bleeding after menopause. Other endometrial cancer symptoms include watery or bloody vaginal discharge, pain in the lower abdomen or pelvis, and pain during sex. Examining the pelvis, using sound waves to create a picture of the uterus, using a scope to examine the endometrium, removing a tissue sample for testing, and performing surgery to remove tissue for testing are all tests and procedures used for endometrial cancer diagnosis.
Endometrial Cancer Epidemiology Segmentation
As per the assessment done by DelveInsight, it was found that Europe has some of the highest rates of uterine cancer in the world; more than 1 in 20 female cancers affect the endometrium, and the number of cases is increasing.
The endometrial cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases
- Stage-specific Incident Cases
- Drug Treatment Population by Line
- Age-specific Cases
Download the report to understand which factors are driving endometrial cancer epidemiology trends @ Endometrial Cancer Epidemiological Insights
Endometrial Cancer Treatment Market
Endometrial cancer treatment options and a variety of factors, including the type and stage of cancer, potential side effects, overall health, age, and personal preferences influences recommendations. This includes whether or not the treatment will have an effect on one’s fertility. Uterine cancer is treated with one or more treatments, including surgery, radiation therapy, and systemic medications. Combinations of these cancer treatments are frequently recommended, but the stage and characteristics of cancer determine their effectiveness.
Endometrial cancer treatment options include surgery, radiation therapy, chemotherapy, hormone therapy, targeted drug therapy, immunotherapy, and supportive care. The standard treatment for endometrial cancer is total hysterectomy with bilateral salpingo-oophorectomy. Radiation and chemotherapy are two treatment options. Nonsurgical treatments are available for endometrial hyperplasia of low to moderate risk. Survival is determined by the stage of the disease and histology, with most patients in stages I and II having a good prognosis. Obesity, diabetes, and hypertension are all risk factors for endometrial cancer, so avoiding them may help.
To know more about endometrial cancer treatment, visit @ Endometrial Cancer Treatment Drugs
Key Endometrial Cancer Therapies and Companies
- Lynparza + Imfinzi: AstraZeneca
- Selinexor: Karyopharm therapeutics
- EG-007: Evergreen therapeutics
- IMGN853: ImmunoGen, Inc.
- Pembrolizumab: Merck Sharp & Dohme LLC
- TSR-042: Tesaro, Inc.
- Everolimus: Abbott
- Giredestrant: Roche
- ONC201: Chimerix
- Abemaciclib + Letrozole +/- Metformin: Dana-Farber Cancer Institute/Eli Lilly and Company
- Sacituzumab Govitecan: Alessandro Santin/Gilead Sciences/Yale University
- Atezolizumab + Bevacizumab: University of Oklahoma/Genentech, Inc.
- Copanlisib + fulvestrant: Bayer
- IMGN151: ImmunoGen, Inc.
- Retifanlimab: Incyte Corporation
Learn more about the FDA-approved drugs for endometrial cancer @ Drugs for Endometrial Cancer Treatment
Endometrial Cancer Market Dynamics
The dynamics of the endometrial cancer market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. In addition, the rising awareness of the disease is also propelling the growth of the endometrial cancer market. Eisai Inc. launched Spot Her in March 2021 to break the silence surrounding endometrial cancer and inspire women to listen, advocate, and prioritize their own and other women’s health. SHARE Cancer Support (SHARE), Facing Our Risk of Cancer Empowered (FORCE), and Black Health Matters collaborated on the initiative. Furthermore, the UNC Lineberger Comprehensive Cancer Center will establish the Endometrial Cancer Center of Excellence in November 2021 to advance scientific understanding of the causes, prevention, and clinical treatment of endometrial cancer and to assist researchers in discovering the underlying factors that contribute to black women in North Carolina being twice as likely to die from endometrial cancer. Such developments raise awareness about endometrial cancer, increasing the demand for treatment in the market.
Moreover, the endometrial cancer pipeline is very robust; many potential therapies are being investigated to treat endometrial cancer, and it is safe to predict that the treatment space will significantly impact the endometrial cancer market during the forecast period. The expected introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the endometrial cancer market in the 7MM.
However, the endometrial cancer market growth may be hampered by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the endometrial cancer market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Endometrial Cancer Companies | AstraZeneca, Karyopharm therapeutics, Evergreen therapeutics, ImmunoGen, Inc., Merck Sharp & Dohme LLC, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte Corporation, Eli Lilly and Company, Gilead Sciences, Genentech, and others |
| Key Endometrial Cancer Therapies | Lynparza + Imfinzi, Selinexor, EG-007, IMGN853, Pembrolizumab, TSR-042, Everolimus, Giredestrant, ONC201, Abemaciclib + Letrozole +/- Metformin, Sacituzumab Govitecan, Atezolizumab + Bevacizumab, Copanlisib + fulvestrant, IMGN151, Retifanlimab, and others |
Scope of the Endometrial Cancer Market Report
- Therapeutic Assessment: Endometrial Cancer current marketed and emerging therapies
- Endometrial Cancer Market Dynamics: Attribute Analysis of Emerging Endometrial Cancer drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Endometrial Cancer Market Access and Reimbursement
Discover more about endometrial cancer drugs in development @ Endometrial Cancer Clinical Trials
Table of Contents
| 1. | Endometrial Cancer Market Key Insights |
| 2. | Endometrial Cancer Market Report Introduction |
| 3. | Endometrial Cancer Market Overview at a Glance |
| 4. | Endometrial Cancer Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Endometrial Cancer Treatment and Management |
| 7. | Endometrial Cancer Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Endometrial Cancer Marketed Drugs |
| 10. | Endometrial Cancer Emerging Drugs |
| 11. | Seven Major Endometrial Cancer Market Analysis |
| 12. | Endometrial Cancer Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Endometrial Cancer Market Drivers |
| 16. | Endometrial Cancer Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
Endometrial Cancer Epidemiology Forecast
Endometrial Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometrial Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometrial cancer companies, including GlaxoSmithKline, Eisai Co Ltd, MedImmune, On Target Laboratories, Sutro Biopharma, among others.
Endometriosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others.
Endometriosis Epidemiology Forecast
Endometriosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
Endometriosis Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Endometrial Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
